The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia

Selva-Vera, Gabriel; Balanzá-Martínez, Vicent; Salazar-Fraile, José; Sánchez-Moreno, José; Martinez-Aran, Anabel; Correa, Patricia; Vieta, Eduard; Tabarés-Seisdedos, Rafael
January 2010
BMC Psychiatry;2010, Vol. 10, p47
Academic Journal
Background: Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia when compared with conventional neuroleptics; nevertheless, their heightened ability to improve cognitive dysfunction remains a matter of debate. This study aimed to examine the changes in cognition associated with longterm antipsychotic treatment and to evaluate the effect of the type of antipsychotic (conventional versus novel antipsychotic drugs) on cognitive performance over time. Methods: In this naturalistic study, we used a comprehensive neuropsychological battery of tests to assess a sample of schizophrenia patients taking either conventional (n = 13) or novel antipsychotics (n = 26) at baseline and at two years after. Results: Continuous antipsychotic treatment regardless of class was associated with improvement on verbal fluency, executive functions, and visual and verbal memory. Patients taking atypical antipsychotics did not show greater cognitive enhancement over two years than patients taking conventional antipsychotics. Conclusions: Although long-term antipsychotic treatment slightly improved cognitive function, the switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of these cognitive deficits.


Related Articles

  • COGNITIVE IMPAIRMENTAND PERCEIVED STRESS IN SCHIZOPHRENIC INPATIENTS WITH POST-TRAUMATIC STRESS DISORDER. Pollice, R.; Bianchini, V.; Conti, C. M.; Mazza, M.; Roncone, R.; Casacchia, M. // European Journal of Inflammation (BIOLIFE, s.a.s.);Sep-Dec2010, Vol. 8 Issue 3, p211 

    The rate of lifetime traumas in the general population is high and a great deal of evidence suggests that persons with severe mental illness (SMI) show an even higher degree of vulnerability to trauma throughout their lives. Recent studies report between 13 and 29% of comorbid Post-Traumatic...

  • First-generation antipsychotics still used in schizophrenia.  // PharmacoEconomics & Outcomes News;3/11/2006, Issue 498, p8 

    Discusses research being done on determinants of first- and second-generation antipsychotic drug use in patients with schizophrenia in European countries. Reference to a study by C. Barbui et al published in the March 2006 issue of "International Clinical Psychopharmacology"; Patients with...

  • Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. McKane, J. P.; Robinson, A. D. T.; Wiles, O. H.; McCreadie, R. G.; Stirling, G. S.; Robinson, A D; Wiles, D H // British Journal of Psychiatry;Sep87, Vol. 151, p333 

    In a double-blind study of 38 chronic schizophrenic in-patients, haloperidol decanoate was compared with fluphenazine decanoate as maintenance therapy over 60 weeks. Both drugs were given by injection at 4-week intervals. Haloperidol and fluphenazine were assumed to be equipotent; the mean...

  • Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital. Pilowsky, L.S.; Ring, H.; Shine, P.J.; Battersby, M.; Lader, M. // British Journal of Psychiatry;Jun92, Vol. 160, p831 

    Rapid tranquillisation--giving a psychotropic to control behavioural disturbances--is common in medical practice, yet few surveys describe its use in psychiatric populations. Over five months, 102 incidents, involving 60 patients, were retrospectively surveyed. Patients most often involved were...

  • Case Histories Illustrating the Utility of Sertindole in Clinical Practice. Schuck, Peter; Ameele, Hans van den; Jaanson, Peeter; Ryckmans, Vincent; Hawley, Chris // CNS Drugs;2004 Supplement 2, Vol. 18, p31 

    Many conventional and atypical antipsychotic agents are available for the treatment of schizophrenia. Matching individual patients to the medication that suits them best is often a matter of trial and error. Controlled clinical trials and extensive post-marketing research have shown that the...

  • Benefit of newer antipsychotics not clear cut.  // PharmacoEconomics & Outcomes News;1/17/2004, Issue 444, p8 

    Discusses research being done on the use of antipsychotics by patients with schizophrenia. Reference to a study by M. Percudani et al, published in the November 2003 issue of the "Journal of Clinical Psychiatry"; Effectiveness of atypical antipsychotics in medicating schizophrenics compared to...

  • Active and passive avoidance learning in controls and schizophrenic patients on racemic propranolol and neuroleptics. Gruzelier, John; Thornton, Susan; Staniforth, David; Zaki, Saniha; Yorkston, Neil; Gruzelier, J; Thornton, S; Staniforth, D; Zaki, S; Yorkston, N // British Journal of Psychiatry;Aug80, Vol. 137, p131 

    Normal controls and schizophrenic patients on propranolol as sole drug or combined with neuroleptics showed superior active and passive avoidance learning to schizophrenic patients who were medicated with conventional neuroleptics only. Active avoidance involved responding quickly, passive...

  • Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Juckel, Georg; Schlagenhauf, Florian; Koslowski, Michael; Filonov, Dimitri; Wüstenberg, Torsten; Villringer, Arno; Knutson, Brian; Kienast, Thorsten; Gallinat, Jürgen; Wrase, Jana; Heinz, Andreas // Psychopharmacology;Aug2006, Vol. 187 Issue 2, p222 

    Rational Clinical studies in patients with schizophrenia suggest that atypical neuroleptics are more effective than typical neuroleptics in reducing negative symptoms including apathy and anhedonia. Dysfunction of the dopaminergic reward system may contribute to negative symptoms in...

  • Lithium treatment in schizophrenia and schizo-affective disorders. Delva, N. J.; Letemendia, F. J. J.; Letemendia, F J // British Journal of Psychiatry;Oct82, Vol. 141, p387 

    Between one third and one half of schizophrenic patients appear to benefit from treatment with lithium carbonate. An even higher proportion of schizo-affective patients benefit, some showing complete recovery. Current unfavourable views on the use of lithium in schizophrenia are contested....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics